Overexpression of the HER2 (neu/c-erbB-2) oncogene frequently coincides with an aggressive clinical course of certain human adenocarcinomas. Expression and secretion of aberrant HER2 splice variants has been reported in various cell lines and tissues and can interfere with the oncogenic HER2 activity. Here we demonstrate, using two dierent approaches, that expression of a truncated 100 kDa HER2 variant which encodes the extracellular domain of HER2 (HER-ECD) inhibits growth factormediated tumour cell proliferation. A HER2-ECD cDNA encoding the truncated variant was overexpressed in MCF7 breast cancer cells. HER2-ECD overexpression decreased spontaneous proliferation of MCF7 cells as well as heregulin-mediated soft agar colony formation. Concomitantly, heregulin-induced phosphorylation of HER4 as well as downstream activation of p44/p42 MAP-kinases was decreased. To con®rm these data, ribozymes were targeted to the 3'-untranslated region of the 2.3 kb HER2-ECD mRNA which is spontaneously expressed in MKN7 gastric cancer cells. HER2-ECDtargeted ribozymes downregulated HER2-ECD expression and enhanced EGF-mediated soft agar colony formation of MKN7 cells. In parallel, EGF-induced activation of p44/p42 MAP-kinases and activation of cFos expression were increased in ribozyme-transfected MKN7 cells. Finally, in RT ± PCR we found a trend towards a progressive loss of 2.3 kb HER2-ECD mRNA expression in more advanced gastric tumours. These data show that the HER2-ECD variant inhibits growth factormediated tumour cell proliferation suggesting an important role during the progression of human cancer.
Introduction
The HER2 (neu, c-erbB-2) proto-oncogene encodes a 185 kDa transmembrane receptor-like tyrosine kinase that shares extensive homology with the other three members of the epidermal growth factor receptor family (HER receptor family) (Tzahar and Yarden, 1998) . The HER receptor family establishes an extensive signalling network that plays a major role in processes like oncogenesis and embryogenesis (Tzahar and Yarden, 1998) . HER2 overexpression has been observed in a variety of human epithelial tumours and has been linked to an unfavourable prognosis in patients with breast and ovarian cancer (Slamon et al., 1987 (Slamon et al., , 1989 . Despite extensive eorts no high-anity ligand or receptor-activating mutations of HER2 have been found (Tzahar and Yarden, 1998) . Recently, HER2 has emerged as the preferred low-anity subunit of all other HER receptors (Graus-Porta et al., 1997; Tzahar et al., 1996) , and heterodimeric receptor combinations containing HER2 show superior signal-transducing and cell-growth stimulating capabilities (Graus-Porta et al., 1995; Karunagaran et al., 1996; Pinkas-Kramarski et al., 1996) . Taken together, there is strong evidence that HER2 confers an autocrine growth advantage to tumour cells (Salomon et al., 1995) , and in addition, is responsible for increased paracrine responsiveness of tumour cells to stroma and/or tumour cell-derived EGF-like or heregulin-like growth factors (Hsieh et al., 2000; Lewis et al., 1996) .
Many transmembrane growth factor and cytokine receptors have been reported to have soluble, ligandbinding receptor forms detectable in the conditioned media of tumour cells and in biological¯uids such as serum and urine (Mosley et al., 1989; Petch et al., 1990; Zabrecky et al., 1991) . The widespread occurrence of soluble receptor forms from distinct proteins such as the interleukine-2-receptor (Rubin et al., 1985) , vascular endothelial growth factor (VEGF)-receptor (Kendall and Thomas, 1993) , the HER1 (Petch et al., 1990) HER2 (Zabrecky et al., 1991) or HER3 receptor (Lee and Maihle, 1998) suggests that these molecules may have important physiological roles. These soluble receptor proteins arise through proteolytic cleavage of membrane-anchored full-length receptors (Rubin et al., 1985; Zabrecky et al., 1991) , and/or by alternative splicing or other gene rearrangements that usually produce novel transcripts which code for proteins containing parts of the ECD, but lack the transmembrane and cytoplasmic domains of the full-length receptor (Doherty et al., 1999; Reiter and Maihle, 1996; Scott et al., 1993) .
Soluble truncated HER2 receptors which have been described in vitro and in vivo in a variety of tumour cell lines and tumour samples arise mainly through a proteolytic mechanism. However, there are at least two distinct truncated HER2-ECD proteins which are encoded by variant HER2 mRNA species. First, Scott et al. (1993) described a variant 2.3 kb HER2 mRNA which encodes the ®rst 633 amino acids (aa) containing almost the entire HER2-ECD (subdomains I ± IV). This truncated 100 kDa protein inhibited the growthinhibitory eects of monoclonal HER2 antibodies presumably through an intracellular mechanism of action (Scott et al., 1993) . More recently, another soluble truncated 68 kDa HER2 protein has been described containing the ®rst 340 aa of the HER2 protein (ECD-subdomains I and II) fused to a unique stretch of 79 aa which are encoded by a novel transcript through insertion of an intronic sequence (Doherty et al., 1999) . The secreted 68 kDa protein acts as an autocrine growth-inhibitor in tumour cells in vitro probably through interference with HER receptor dimerization (Doherty et al., 1999) . The potential physiological relevance of soluble truncated HER receptors are largely unexplored.
Here we show, that the 100 kDa HER2-ECD can act as a dominant-negative inhibitor of growth factormediated tumour cell proliferation. Doxycycline-regulated expression of the corresponding 2.3 kb HER-ECD cDNA in transfected MCF7 breast cancer cells showed HER2-ECD-mediated inhibition of spontaneous proliferation as well as inhibition of heregulin-mediated proliferation and signal transduction. Likewise, ribozyme-targeting of the endogenously expressed 2.3 kb HER2-ECD mRNA splice variant in MKN7 gastric cancer cells demonstrated reduction of HER2-ECDmediated inhibition of EGF-mediated proliferation in soft agar and downstream signal-transduction. Furthermore, we provide data from some gastric tumour samples which suggest that reduced HER2-ECD expression is linked with a more aggressive phenotype, thus adding information towards the potential role of soluble truncated HER2 proteins in human tumours.
Results

Genomic structure of the HER2 gene region containing the variant HER2-ECD sequence
Since the aberrantly spliced HER2-ECD mRNA was originally sequenced from cDNA libraries only (Scott et al., 1993) , and since genomic sequence from this particular HER2 gene region is not yet available, we decided to use genomic sequencing in order to verify whether the divergent sequence is contiguous in the genome. Partial sequencing of a P1 phagemid clone con®rmed the originally described exon/intron boundary, the in-frame stop codon and the novel polyadenylation signal of the divergent sequence followed by an intron of approximately 2.6 kb length (Figure 1a ).
Regulated expression of the 100 kDa HER2-ECD variant in MCF7 breast cancer cells
In order to study the biological role of the 100 kDa truncated HER2 protein, we chose MCF7 breast cancer cells as a model. MCF7 cells do not endogenously express the divergent HER2 mRNA, express only low levels of the full-length HER2 protein and respond very well to heregulin. We used a tetracyline-regulated expression system (tet-o system) as described (Juhl et al., 1997) to generate MCF7 cells overexpressing the 2.3 kb HER2-ECD mRNA. Cell surface expression of full-length HER2, HER3 and HER4 receptors was measured by FACS analysis and remained unaltered in transfected MCF7 cells as compared to MCF7 wildtype cells (data not shown). Northern analysis of stably transfected MCF7-HER2-ECD cells showed that the 2.3 kb HER2-ECD mRNA was eectively expressed in the absence of doxycycline (Figure 2a ; 7dox) and that HER2-ECD mRNA expression could be repressed by more than 90% upon addition of doxycycline (Figure 2a, b; +dox) . In addition, Western blot analysis from total cellular lysates revealed high expression levels of a single protein at approximately 100 kDa in the absence of doxycycline, representing the truncated HER2-ECD protein (Figure 2c ; 7dox vs +dox). Next we asked, whether the overexpressed HER2-ECD protein was also found in the conditioned media of transfected MCF7 cells. To that end a quantitative HER2 ELISA was used. In cellular lysates the truncated HER2-ECD protein was expressed at approximately 10-fold higher levels in the absence of doxycycline (Figure 2d ; left panel) which correlated very well with the results from the Western analysis (Figure 2c ). Signi®cant amounts of HER2-ECD protein were also detected in the conditioned media (Figure 2d ; right panel), demonstrating that the truncated HER2-ECD protein was eectively secreted in transfected MCF7 cells. The low abundance of full-length 185 kDa HER2 protein expression ( Figure 2c ) together with the marked dependence of the measured HER2 levels on the doxycycline treatment indicates that the HER2 ELISA detects truncated HER2-ECD protein that is secreted into the media rather than shedded HER2-ECD from membrane anchored full-length HER2 protein.
HER-ECD expression inhibits spontaneous as well as heregulin-mediated proliferation in MCF7 cells
In the next series of experiments the impact of HER2-ECD overexpression on proliferation of MCF7 breast cancer cells was addressed by anchorage-dependent as HER2-ECD variant acts as inhibitor of tumour cell proliferation A Aigner et al well as anchorage-independent growth assays. HER2-ECD expression inhibited proliferation of MCF7 cells grown attached to plastic surfaces by approximately 50% (Figure 3a) . Additionally, high levels of HER2-ECD expression signi®cantly inhibited heregulinmediated soft agar colony formation of MCF7 cells (Figure 3b ; 7dox vs +dox). Next we tested if the HER2-ECD eects on heregulin-mediated colony formation were paralleled by a similar inhibition of downstream signal-transduction events. As expected, stimulation of serum-starved cells with heregulin (10 79 M) increased the phoshorylation levels of the HER2 and the HER4 receptors (Figures 4a,b) . A time course experiment showed that the heregulin-mediated increase of phosphorylation of the HER4 receptor was reduced and occurred with a time delay in HER2-ECD overexpressing cells (Figure 4b ; 7dox vs +dox). This reduction of HER4 receptor phosphorylation was followed by a similar inhibition of downstream signalling events such as activation of p44/p42 MAPkinases (Figure 4c,d ) and induction of c-Fos mRNA expression (data not shown). Since Scott et al. (1993) had previously proposed an intracellular mechanism of action based on interference of HER2-ECD with receptor internalization and recycling, we tested if the recovery of cell surface expression of HER2 and HER3 receptors after heregulin-induced internalization was altered by HER2-ECD expression. There was no in¯uence of HER2-ECD overexpression on the recovery time of cell surface expression of any of the HER2 and HER3 receptors in MCF7 cells (data not shown).
Ribozyme-mediated downregulation of endogenous HER2-ECD expression in MKN7 gastric cancer cells
As a second model we applied a ribozyme targeting strategy to speci®cally downregulate HER2-ECD mRNA expression in MKN7 gastric cancer cells. MKN7 cells were originally described as the only tumour cell line with very high expression levels of truncated as well as full-length HER2 proteins (Scott et al., 1993) . A hammerhead ribozyme was designed to speci®cally cleave in the unique 3'-untranslated region of the 2.3 kb HER2-ECD mRNA and stable masstransfected HER2-ECD ribozyme expressing MKN7 cells were generated (MKN7/Rz-ECD3). Using this approach we expected to degrade the mRNA of the aberrantly spliced 2.3 kb HER2-transcript while leaving the mRNA of the full-length 4.5 kb HER2 transcript intact, thus altering the ratio of full-length Figure 1 Schematic diagram of the HER2 gene region containing the divergent HER2-ECD sequence and overview of the protein domain structure of the full-length and the truncated HER2 proteins. (a) Genomic DNA from a phagemid P1 clone containing the HER2 region of interest was partially sequenced and the sequence of three previously unknown HER2 exon/intron boundaries are shown. The boxed sequences contain exon sequence, and the intronic sequence of the adjacent exon/intron boundaries is shown on the horizontal lines when sequence information was available. The numbering on top of the exon borders represents the position in the full-length HER2 cDNA relative to the ATG in the translation start site. In the expanded brackets the divergent region of the 3'-terminus of the truncated HER2-ECD mRNA is shown with the retained 5'-splice donor site (GTGAG), the in-frame stop codon (TGA) and the polyadenylation signal (ATTAAA, underlined). The line on top of the HER2-ECD mRNA represents the target sequence of Rz-ECD3 hammerhead ribozyme designed to speci®cally cleave at the TTC' in the 3'-untranslated region of the HER2-ECD mRNA. (b) The top diagram shows the schematic structure of the full-length (1253 amino acids) 185 kDa HER2 protein with the subdomains I, II, III and IV in the extracellular domain (ECD), the transmembrane domain (TM) and the cytoplasmic kinase domain (CytD). The diagram on the bottom illustrates the truncated HER2-ECD protein which is identical with the ®rst 633 aa of the full-length HER2 protein and thus contains almost the entire HER2-ECD except for the most 3' 25 aa next to the TM-domain to truncated HER2 mRNA in MKN7 cells. Northern analysis (Figure 5a ) demonstrated that Rz-ECD3 transfected MKN7 cells showed comparable levels of full-length HER2 mRNA while the truncated HER2-ECD mRNA was reduced by approximately 70% (Figures 5a,b) . Western blot experiments from total cellular lysates showed a parallel reduction of the truncated 100 kDa HER2-ECD protein (data not shown), while FACS analysis demonstrated that there was no change in cell surface expression levels of HER1, HER2 or HER3 receptors (data not shown).
Endogenous HER-ECD expression inhibits EGF-mediated proliferation and signal transduction in MKN7 cells
In order to test the biological signi®cance of reduced expression of the truncated HER2-ECD in MKN7
Figure 2 Doxycycline-regulated overexpression of a truncated HER2-ECD cDNA coding for a 100 kDa HER2 protein variant (HER2-ECD) in MCF7 breast cancer cells. (a) Total RNA (20 mg) from MCF7 cells stably expressing a 2.3 kb HER2-ECD mRNA under the control of a doxycycline-regulated promoter was analysed by Northern blotting for HER2-ECD mRNA expression in the absence (7 dox) or presence (+ dox) of doxycycline (2 mg/ml). (b) HER2-ECD mRNA expression was quanti®ed relative to G3PDH by phosphorimaging. (c) MCF7 cell lysates were prepared as described and equal amounts of protein were separated on a denaturing 4 ± 20% polyacrylamide gradient gel. The blots were probed with an anti-HER2-ECD-antibody which is able to detect truncated as well as full-length HER2 protein forms. (d) A quantitative HER2 ELISA assay was used to determine HER2-ECD protein levels in total cellular lysates and in conditioned media of transfected MCF7 cells grown in the absence or presence of doxycycline (2 mg/ml). HER2 levels (mean+s.d.) were calculated according to a HER2 standard curve generated from recombinant HER2 as supplied by the manufacturer (data not shown)
HER2-ECD variant acts as inhibitor of tumour cell proliferation
A Aigner et al cells, we tested the responsiveness to EGF in wildtype vs ribozyme-transfected cells. Soft agar colony formation of wildtype MKN7 cells was stimulated by EGF in a dose-dependent manner but there was only a slight approximately threefold maximum stimulation at 3 ng/ ml of EGF ( Figure 6 ). In contrast, ribozyme transfected MKN7 cells with reduced levels of HER2-ECD showed a signi®cantly enhanced responsiveness towards EGF with a maximum 10-fold stimulation. Next we tested in serum starved MKN7 cells whether these dierences in EGF responsiveness could be attributed to changes in downstream signalling events. Serum-starved MKN7 cells with reduced levels of HER-ECD showed an approximately threefold higher induction of p44/p42 MAP-kinases after 30 min of EGF treatment as compared to wildtype cells ( Figures  7a,b) . In addition, ribozyme-transfected MKN7 cells showed an approximate twofold higher induction of cFos mRNA expression after 30 min of EGF treatment as compared to wildtype cells (Figures 7c,d ).
Since, as mentioned above, impairment of receptor recycling had been proposed as one possible mechanism of intracellular HER2-ECD action, we tested if recovery of HER1 and/or HER2 cell surface expression after discontinuation of EGF treatment was altered in ribozyme-transfected MKN7 cells. Again, as in MCF7 cells, the rate of HER1 and HER2 receptor internalization and time course of recovery of surface expression showed no signi®cant dierences between ribozyme-transfected and wildtype MKN7 cells (data not shown).
HER-ECD expression is reduced in more advanced gastric tumours
Since our data suggest that HER2-ECD expression can act as an inhibitor of tumour cell proliferation mediated by ligands of the HER receptor family, we asked whether this biological role of the truncated HER2 protein in vitro could also be observed in tumour samples in vivo. In a pilot study, expression of HER2-ECD as well as HER2 full-length mRNA was determined by RT ± PCR. RT ± PCR for the full-length HER2 transcript was positive in all 14 cases as compared to only seven out of 14 positive cases for the truncated HER2 transcript (Table 1) . When the tumour samples were categorized according to TNM stages (I ± IV) and biological grades (G1 ± G3) there was a trend towards reduced HER2-ECD expression in tumours with higher stages (IV) and biological grades ( Table 1 ; three out of nine positive cases in G3 compared to four out of ®ve in G2). It appears that loss of HER2-ECD expression could act as a positive selection event for gastric tumour cells.
Discussion
Alternative splicing of HER2 preRNA generates at least three distinct mRNA's encoding the 185 kDa fulllength membrane-spanning receptor that confers oncogenic activity and two truncated and soluble HER2-ECD proteins that are able to interfere with this activity. The ®rst soluble HER2 receptor was described by Scott et al. (1993) as a 100 kDa HER2-ECD protein derived from a 2.3 kb HER2 transcript. Despite the presence of a canonical 5'-splice donor site, the sequence diverges in the truncated transcript at nt 1898 (with nt 1 counted as the translation start-site), Figure 3 Spontaneous as well as heregulin-mediated proliferation are reduced in MCF7 cells overexpressing the HER2-ECD protein. (a) To determine anchorage-dependent proliferation rates, 250 cells were plated in triplicates into 96-well plates and grown in the absence (7dox) or presence (+dox) of doxycycline with addition of 10% serum. Cell numbers were quanti®ed at dierent time points using a colorimetric assay and are presented as x-fold stimulation (mean+s.e.m. from three independent experiments) over background levels (background=cell numbers 24 h after plating (day 1) for each cell line). (b) 10 4 cells were plated in soft agar as described and grown in the absence (7 dox) or presence (+ dox) of doxycycline with addition of heregulin in the indicated concentrations. Soft agar colonies 460 mm were counted after 10 days of incubation and are presented as x-fold stimulation (mean+s.d. from three independent experiments) over background levels (background=no heregulin treatment) revealing an exonic extension with an in-frame stop codon and a novel polyadenylation site. Here, sequencing of this particular HER2 gene-region con®rmed the 5'-exon/intron boundary and the genomic contiguity. Thus it appears plausible that the truncated 2.3 kb HER2 mRNA arises from the absence of processing of this particular 5'-splice site resulting in a direct read-through of the contiguous intron sequence. Recently, another 2.6 kb HER2 mRNA variant has been described coding for a secreted 68 kDa protein (Doherty et al., 1999) . Both variants seem to be expressed only at low levels in tumour cells and tumour tissues, but are expressed at higher abundance in normal non-transformed cells.
Similar splice-site skipping of 3-introns have been described to occur in various other genes, including interleukin-5-receptor a-subunits (Tavernier et al., 1992) , avian EGF-receptor (Flickinger et al., 1992) and the VEGF-receptor (Kendall and Thomas, 1993) . Production of alternatively transcribed soluble recep- Figure 4 Heregulin-mediated phosphorylation of HER2 and inhibition of heregulin-mediated induction of phosphorylation of HER4 and p44/p42 MAP-kinases in HER2-ECD overexpressing MCF7 cell lines. MCF-7 cells grown in the absence (7dox) or presence (+dox) of doxycycline (2 mg/ml) as indicated in the ®gures were serum starved for 48 h and then treated with heregulin (10 79 M) for the indicated time points. For Western blotting, total cellular lysates were prepared as described and equal amounts of proteins were separated on 4 ± 20% polyacrylamide gels or immunoprecipitated and separated on denaturating 8% polyacrylamide gels. (a) After 10 min (+) vs no (7) heregulin stimulation, cellular lysates were immunoprecipitated with an anti-phosphotyrosine antibody. HER2 were detected with anti-HER2 antibodies (Ab 17) and HER-2-speci®c bands (right panel, arrow) were quanti®ed by densitometry (left panel). (b) Cellular lysates were immunoprecipitated with anti-HER4 antibodies and phosphorylated HER4 was detected with an anti-phosphotyrosine antibody (upper panel). Bands were quanti®ed by densitometry (bars). (c) Activated forms of p44/p42 MAP-kinases were detected with an antibody that is speci®c for the phosphorylated forms of p44/p42, and (d) were quanti®ed by densitometry (bars represent the sum of p44 and p42 signal intensities)
HER2-ECD variant acts as inhibitor of tumour cell proliferation
A Aigner et al tors could provide a mechanism for selectively and eciently inhibiting cellular responsiveness to speci®c mitogenic and dierentiation factors. These soluble receptors could exert their function through binding of their cognate ligands, or through interference with receptor dimerization and thus could act as speci®c high-anity inhibitors in vitro and in vivo. It was originally described that HER2-ECD expression abrogated the growth-inhibition mediated by monoclonal anti-HER2-antibodies, and HER-ECD overexpression in transfected BT474 breast cancer cells which were selected in the presence of cytostatic doses of the anti-HER2-antibodies led to enhanced proliferation rates (Scott et al., 1993) . This in contrast to the decreased proliferation rates of transfected NIH3T3 cells as well as various tumour cells treated with recombinant 68 kDa HER2-ECD protein (Doherty et al., 1999) . However, it is possible that the enhanced proliferation of BT474 cells was an indirect eect due to the selection pressure exerted by the anti-HER2-antibody rather than a direct growth stimulatory eect exerted by the truncated 100 kDa HER2 variant. To address this issue, we used a tightly regulated expression system (tet-o system) to express the HER2-ECD in MCF7 cells. Using this approach, we observed that overexpression of the 100 kDa variant inhibited spontaneous as well as heregulin-mediated proliferation of MCF7 cells. Thus, since we used a tightly controlled expression system, it appears that in contrast to the previously described data in BT474 cells, it is more likely that the 100 kDa protein acts as an inhibitor of spontaneous tumour cell proliferation which is concordant with data obtained with the 68 kDa HER2 (Doherty et al., 1999) . The same role of the 100 kDa variant as an endogenous inhibitor of paracrine tumour cell proliferation was also observed in MKN7 gastric cancer cells that endogenously overexpress this truncated HER2-ECD form approximately in a 1 : 1 ratio with the full-length receptor. Ribozyme-trans- (a) MKN7 wildtype cells and MKN7 cells transfected with the Rz-ECD3 ribozyme construct were serum-starved for 48 h and then treated with EGF (10 ng/ml) for the indicated time points. Total cellular lysates were prepared as described and equal amounts of proteins were separated on a denaturing 4 ± 20% polyacrylamide gradient gel. Activated forms of p44/p42 MAP-kinases were detected with an antibody that is speci®c for the phosphorylated forms of p44/p42, and (b) were quanti®ed by densitometry (®lled bars (wildtype) and open bars (Rz-ECD3) represent the sum of p44 and p42 signal intensities). (c) In parallel experiments, total RNA was prepared from cells grown under the same experimental conditions and analysed by Northern blotting for c-Fos mRNA expression as described. c-Fos mRNA expression was quanti®ed relative to G3PDH by phosphorimaging (d)
A Aigner et al 100 kDa protein as an endogenous inhibitor of paracrine tumour cell proliferation in a dierent model system. Based on the high and predominantly perinuclear expression levels of the 100 kDa protein, an intracellular mechanism of action had originally been proposed (Scott et al., 1993) , in which the 100 kDa HER2 form somehow interferes with the assembly of functional receptor dimers or inhibits the receptor recycling process after ligand-induced receptor internalization. In our studies we found no in¯uence of HER2-ECD expression on ligand-induced receptor internalization rates or recovery of cell surface expression of HER1, HER2 or HER3 receptors in MCF7 or MKN7 cells. In contrast, HER-ECD expression reduced heregulin-mediated phosphorylation of HER4 receptors as well as downstream signalling events such as activation of p44/p42 MAPkinases and c-Fos expression. These observations, together with our data that signi®cant amounts of the 100 kDa HER2-ECD are secreted and thus can act extracellularly, suggest that the major mechanism of inhibitory action of the 100 kDa HER2-ECD variant is similar to the proposed model for the 68 kDa protein, where extracellular inhibition of HER2 receptor dimerization was demonstrated. Whatever the precise mechanism of soluble HER-ECD action is, the expression of soluble HER2 receptor forms could provide a selective pressure for reduced expression of truncated HER2-ECD proteins to overcome the growth-inhibition exerted by the truncated ECD forms in tumour cells. Indeed, when we tested for expression of the truncated and of the full-length HER-ECD transcripts in some gastric tumour samples, a tumour where HER2 expression is an independent marker of tumour progression and invasiveness (Allgayer et al., 2000) , we observed a trend towards a progressive loss of HER-ECD expression in more advanced tumours. Clearly, these results need to be con®rmed in a larger number of tumour samples, especially since in 15 tumour samples from breast cancer patients HER-ECD expression was found to correlate with the development of micrometastases (Gebhardt et al., 1998) . It remains to be answered if the role of HER-ECD expression is dependent on the tumour type or other confounding variables.
It is conceivable that soluble HER2-ECD variants could be used as inhibitors of tumour growth in vivo.
On the other hand one needs to consider reports that high HER2-ECD serum levels in cancer patients were inversely correlated with the response to chemotherapy (Colomer et al., 2000) . Further studies concerning the distribution of HER-ECD expression in normal vs malignant tissues and during dierent stages of tumour development are needed. Likewise, the in¯uence of HER2-ECD expression on established tumour treatments like chemotherapy, hormone treatment and radiation needs to be investigated in order to better understand and therapeutically exploit the important HER receptor network.
Materials and methods
Plasmids and generation of constructs
Plasmid expressing the tetracycline transactivating (tTA)/ VP16 fusion protein (pUHG15 ± 1;) and the tTA/heptametrical operator binding site (tet-O; pUHC13 ± 3;) were obtained from Dr Boujard (Heidelberg, Germany). The HER2-ECD expression plasmid (pTET) was derived from pUHC13 ± 3 and modi®ed as described (Schulte et al., 1996) . A 1.95 kb HER2-ECD BstXI-fragment was cut from pw597.3a plasmid DNA containing a cDNA coding for the entire 2.3 kb HER2-ECD was cloned into the BstXI site of pTET (pTET-HER2-ECD). The hammerhead ribozyme Rz-ECD3 targeted speci®cally to the unique 3'-untranslated region (UTR) of the 2.3 kb HER2-ECD mRNA was designed to cleave 39 nt downstream of the unspliced exon/ intron boundary and was cloned into the pRc/CMV expression plasmid (Invitrogen, San Diego, CA, USA) as described (Czubayko et al., 1994) . In brief, the following Rz-ECD3 ribozyme coding sense and antisense oligonucleotides: 5'-agcttCCTGAAAGCTGATGAGTCCGTTAGGACGAAAAAGTCCAa-3' (sense) and 5'-agcttAGGACTTTTTCGTCC-TAACGGACTCATCAGCTTTCAGGA-3' (antisense) with small letters indicating HindIII-restriction site overhangs; bold capital letters showing HER2-ECD speci®c antisense regions; and italic capital letters indicating the hammerhead ribozyme core sequence, were annealed together and ligated into the HindIII-restriction site of pRc/CMV. P1 library screening and HER2 intron sequencing PCR screening of a human P1 Library (Genome Systems, St Louis, MO, USA) was performed using primers 5'-CTGCTGGTCTGTGTCTTGGG-3' (1881) and 5'-CCGTTTCCTGCAGCAGTCTCC-3' (2066rev). The P1 clone obtained from screening was subcloned (shotgun subcloning, Genome Systems, St Louis, MO, USA) in the pZERO-1 vector (Invitrogen, Carlsbad, CA, USA) using HindIII and XbaI. Subclones with an average insert size of 7 ± 10 kb were screened with the same primers, and from positive subclones DNA was prepared as described (Genome Systems, St Louis, MO, USA). For sequencing into intron regions, various primers from exon regions were used. From the intronic sequence new primers were deduced to obtain additional intron sequence information.
Cell lines, transfections and growth assays
MCF7 and MKN7 cell lines were maintained in culture at 378C/5% CO 2 using Iscove's modi®ed Dulbecco's medium (IMDM, PAA Laboratories, CoÈ lbe, Germany) supplemented with glutamine and 10% heat-inactivated foetal bovine serum (FBS, PAA Laboratories). MKN7 cells were transfected using LipofectAMINE (Life Technologies, Bethesda, MD, USA) as described (Juhl et al., 1997) and stable masstransfected cells were selected with G418 at 1 mg/ml. MCF7 cells stably expressing a tetracycline regulated 2.3 kb HER2-ECD mRNA were generated in a two-step transfection protocol as described (Juhl et al., 1997) . In a ®rst step, MCF7 cells were transfected with pUHG15-1 plasmid DNA and pRc/CMV plasmid DNA (Invitrogen, San Diego, CA, USA) in a 10 : 1 ratio to provide G418 resistance. After selection for stable integrants in the presence of G418 at 0.7 mg/ml, individual tTA expressing clones were isolated with cloning rings and the clone (MCF7-600-10) that demonstrated the tightest tetracycline regulation was used for further transfections with the pTET/HER2-ECD plasmid. MCF7-600-10 cells were transfected with pTET/HER2-ECD plasmid DNA mixed with pZero plasmid DNA (Invitrogen) in a 10 : 1 ratio to provide Zeocin resistance. Mass-transfected derivative cell pools were obtained after 6 weeks of selection with 0.4 mg/ml Zeocin in the continuous presence of 2 mg/ml doxycycline to repress transgene expression during the selection period.
To determine anchorage-dependent proliferation rates of transfected MCF7 and MKN7 cell lines, 250 to 1000 cells were plated in triplicates into 96-well plates and cell numbers were quanti®ed at dierent time points using a colorimetric assay, which is based on the cleavage of a tetrazolium salt by mitochondrial dehydrogenases in viable cells (Cell Proliferation Reagent WST-1, Boehringer Mannheim, Mannheim, Germany). Studies of anchorage-independent growth of MCF7 and MKN7 cells were carried out as described (Czubayko et al., 1994) . Brie¯y, 10 4 cells in 0.35% agar (Difcoagar, Life Technologies) were layered on top of 1 ml of a solidi®ed 0.6% agar layer in a 35 mm dish. EGF (Life Technologies; ®nal concentrations ranging from 0.1 to 100 ng/ml) or heregulin (Neomarkers, Fremont, CA, USA, ®nal concentrations ranging from 0.1 to 30 ng/ml) were added to the top layer mixture. Normal growth media with 10% FBS were included in both layers. In order to obtain better stimulation of colony formation of MCF7 cells by heregulin, the high levels of oestrogen-mediated spontaneous colony formation were reduced by a complete oestrogen receptor antagonist (ICI 182.780; Tocris, Bristol, UK) which was added to the top layer to a ®nal concentration of 10 78 M.
Northern analysis
Total cellular RNA was isolated with the RNA STAT-60 method (Tel-Test, Friedenswood, TX, USA), and 20 mg were separated and blotted as described (Czubayko et al., 1994) . Human cDNA probes speci®c for HER2 (1.5 kb EcoRI fragment from the HER2-ECD coding region) or c-Fos (900 bp AccI fragment) were hybridized, washed and exposed to ®lm for 24 h (HER2) or 72 h (c-Fos). To correct for variability in loading, blots were stripped, reprobed with a glyceraldehyde-3 phosphate dehydrogenase (G3PDH, Clontech, Palo Alto, CA, USA) cDNA probe and exposed to ®lm for 6 h. Relative band intensities were measured by phosphorimaging.
Immunoprecipitation and Western analysis
For immunoprecipitation, 48 h serum-starved cells at 50 ± 70% con¯uency were treated with heregulin prior to preparation of cell lysates as described (Souttou et al., 1997) . Brie¯y, 1 mg of protein was incubated overnight at 48C with 20 ml of 4G10 anti-phosphotyrosine antibody coupled to agarose beads (UBI) or 2 mg of antibodies speci®c for HER4 (Neomarkers, Fremont, CA, USA; clone Ab 1). Immunocomplexes were captured with Protein G-Sepharose (HER4) at 48C for 2 h. Beads were then washed in IP buer and proteins eluted by boiling in SDS ± PAGE sample buer. Cells for Western analysis without prior immunoprecipitation were lysed in lysis buer (2% SDS, 20% 2-mercaptoethanol, 10% glycerol). Western analysis was performed essentially as described (Aigner et al., 2000) . Brie¯y, equal amounts of proteins were separated on denaturating, reducing 8% or 4 ± 20% polyacrylamide gels and tranferred onto a nitrocellulose membrane (Protran BA 83, Schleicher & Schuell, Keene, NH, USA). After blocking with 3% BSA in TBS/0.05% Tween-20 (=TBST), the membrane was washed in TBST and probed in the same buer with anti-HER1, 1 : 10 000 (Neomarkers, Ab 3), anti-HER2, 1 : 100 (Neomarkers, Ab 3), anti-HER2, 1 : 400 (Neomarkers, Ab 17), 4G10 anti-phosphotyrosine antibody, 1 : 1000 (UBI), or anti-p44/p42 MAPK, 1 : 1000 (New England Biolabs, Beverly, MA, USA) which are speci®c for the phosphorylated forms of p44/p42-kinases, respectively, for 1 or 2 h as recommended by the supplier at room temperature. After extensive washing with TBST, bound antibodies were visualized by chemiluminescence using HRP-conjugated sheep anti-mouse antibodies and ECL detection reagents (Amersham, Buckinghamshire, UK). Band intensities were measured by densitometry (1D Image Analysis Software, Eastman Kodak Company, Rochester, NY, USA).
HER2 ELISA
Levels of intracellular and secreted HER2 were determined by ELISA (Oncogene, Cambridge, MA, USA) according to the manufacturer's protocol with modi®cations in the sample preparation. 6610 5 cells were grown for 48 h, the conditioned medium was collected, centrifuged, diluted 1 : 50 in sample diluent and directly used in the ELISA. The cells were washed twice with PBS and were lysed with 1.5 ml receptor buer. After scraping, the lysate was transferred into a 2 ml vial, sonicated for 5 min and subjected to three freeze-thaw cycles to complete lysis. Fifty ml of the lysate were mixed with 10 ml antigen extraction buer and incubated for 5 min. After centrifugation and determination of the protein concentration by BioRad assay, the supernatant was diluted in sample diluent to a ®nal protein concentration of 5 mg/ml and measured in the ELISA.
Fluorescence-activated cell sorting (FACS)
Cell surface expression of the four HER receptor family members was quantitated by FACS-analysis as described (Hsieh et al., 2000) . Brie¯y, cells were incubated for 30 min at 48C with 1 : 50 dilutions of primary anti-human mouse monoclonal antibodies speci®c for HER1 (Clone EGFR1; Neomarkers), HER2 (Clone 9G6.10; Neomarkers), HER3 (Clone H3.90.6) or HER4 (Clone H4.77.16), and labelled with a 1 : 200 diluted FITC-labelled goat anti-mouse secondary antibody (Boehringer Mannheim). The mean value of¯uorescence intensity of 10 000 cells was determined by FACS (FACStar plus; Becton Dickinson, Franklin Lakes, NJ, USA).
RT ± PCR
Total RNA from frozen gastric tumour samples was prepared and 2 mg of RNA were included in each RT ± PCR reaction.
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